Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
about
Light chain (AL) amyloidosis: update on diagnosis and managementCD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyFifty years of melphalan use in hematopoietic stem cell transplantationUpdate on treatment of light chain amyloidosisAmyloid diseases of the heart: current and future therapiesDiagnosis and management of neuropathies associated with plasma cell dyscrasias.Amyloidosis: pathogenesis and new therapeutic options.Updates in cardiac amyloidosis: a review.Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.Splenic plasma cells can serve as a source of amyloidogenic light chainsLong-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.The burden of amyloid light chain amyloidosis on health-related quality of life.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.New insights and modern treatment of AL amyloidosis.Immunoglobulin light chain amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.Disease burden of systemic light-chain amyloidosis: a systematic literature review.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report.Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.Current treatment of AL amyloidosis.Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.AbstractsResults of autologous stem cell transplantation for AL amyloidosis in one Czech center
P2860
Q21198863-ADA98D2F-092C-4DE1-BEC3-0FB48D519FDEQ24649764-52A980A3-7072-4691-B345-B704071B5F59Q26824498-98323A61-7F60-4DDF-995A-DFE13FC7D913Q26829735-65CE50CA-F536-4FC3-B462-85DEB26D7636Q27023836-D45607B0-4F9A-4EF5-9CF9-56026D2FF79DQ34555067-553217E8-434B-4B49-B7D0-3EA8E3CCB293Q35111771-15FAFF87-8CB1-4D62-8C69-D77E1EE578ABQ36366356-5C0C23AC-2DDF-4D8E-8CD6-D67D94977BEDQ36384780-88C8D289-C647-4248-A22B-6327C94A846EQ37059137-35075468-8A7F-4816-A332-FF44497934CAQ37100733-0A48212F-0019-49AA-9504-37DF8D71BB52Q37570615-C7E3656F-173D-43B4-A281-92768CF4B327Q37593524-70C424F3-7050-4EE6-9416-24CC7973BA24Q37904673-F3B08FD8-9A11-43A4-A162-F928420479A1Q37999957-AEB39E3A-397F-4C87-AEF3-C2876DC11EBAQ38056010-66B65128-E00C-4A82-9D8A-C362F001256AQ38072108-83D62E3C-25F9-4100-920E-8601C7AFBBEEQ38100588-78B3F4AC-3FAE-4D4D-B42E-065A7D306F50Q38136576-6C474311-0E83-4B22-996E-F7BA2460C970Q38172295-314CAFF6-B56D-41BB-9812-652AAD923964Q38172998-A054F0F6-B2E4-4868-A0AF-0628ACC0A01BQ38917828-7D776A3F-C126-4D08-ACF8-46654C10640CQ41021929-652A9644-FA9E-49A3-BCDF-57FFE9694716Q42391620-21B37E77-AEE2-418F-91BB-1354E9601F77Q42543905-D72EBCEC-6DBC-43EB-81CC-2E866A06F941Q42662215-5BE1CDDB-3A9A-4C64-AB5E-16DAB603FAA3Q43945212-84BC1F8E-1507-4653-85CF-24AB3F23010FQ46251291-DF908A25-1EE1-47E7-9700-F1D67DE7E328Q48156924-C0EB173A-509D-49C2-BD1C-4C92988F4ABFQ48382207-82965ABB-CC17-4BD6-922F-F8D15597493FQ51683327-B7C8C53F-41BC-4D6C-9FB4-DBF56B0A861DQ53081939-CC53C047-737F-4C4B-B5CE-CE2454CF0977Q57259399-C8E6CFF8-2E11-48C1-A5F1-C9220B67CDC6Q58125071-D804A7F7-02F8-4784-9A80-FE1AD6CFFD2F
P2860
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Risk-adapted autologous stem c ...... : results of a phase II trial.
@en
Risk-adapted autologous stem c ...... : results of a phase II trial.
@nl
type
label
Risk-adapted autologous stem c ...... : results of a phase II trial.
@en
Risk-adapted autologous stem c ...... : results of a phase II trial.
@nl
prefLabel
Risk-adapted autologous stem c ...... : results of a phase II trial.
@en
Risk-adapted autologous stem c ...... : results of a phase II trial.
@nl
P2093
P2860
P921
P1476
Risk-adapted autologous stem c ...... s: results of a phase II trial
@en
P2093
Beth Levine
Daniel A Filippa
Elyn Riedel
Hani Hassoun
Joanne Chou
Julie Teruya-Feldstein
Lilian Reich
Martin Fleisher
Michael D Stubblefield
P2860
P304
P356
10.1111/J.1365-2141.2007.06783.X
P407
P50
P577
2007-10-01T00:00:00Z